Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2Recurrence 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Dexamethasone 238Lenalidomide 145daratumumab 123Bortezomib 101pomalidomide 86Calcium Dobesilate 76carfilzomib 74Cyclophosphamide 70Specimen Handling 42isatuximab 40Biopsy 40fludarabine 36belantamab mafodotin 36Magnetic Resonance Spectroscopy 35talquetamab 29dexamethasone acetate 27dexamethasone 21-phosphate 27Melphalan 27auricularum 26iberdomide 25ixazomib 22fludarabine phosphate 22selinexor 21elotuzumab 21Whole-Body Irradiation 14X-Rays 13tocilizumab 12venetoclax 11Mycophenolic Acid 10trametinib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Multiple Myeloma × Fumigant 93 × 1 year × Clear all
NCT07623798 2026-06-03

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Not yet recruiting
255 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT05900882 2025-08-17

SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
35 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡